lobbying_activities: 2424161

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2424161	ed1f9520-700a-4328-ac42-dba0018eabb1	Q1	MARSHALL & POPP, LLC	401105121	SANOFI U.S. SERVICES, INC.	2020	first_quarter	PHA	Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19/S.3129: Lower Costs, More Cures Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index. Issues related to the COVID-19 pandemic. H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. H.R.6201: Families First Coronavirus Response Act. H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),SENATE,White House Office	60000		0	0	2020-04-13T15:17:32.377000-04:00